#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians managing patients with cannabis use disorder now have updated evidence-based treatment protocols and withdrawal management strategies to improve outcomes and reduce relapse rates. Understanding current pharmacological and behavioral interventions is essential as cannabis use prevalence continues to rise across age groups, requiring geriatric and adolescent specialists to address addiction appropriately within their respective populations. Equipping clinicians with the latest clinical data on cannabis addiction treatment directly improves patient safety, reduces unnecessary emergency department visits, and supports medication-assisted therapy options when indicated.
Recent clinical evidence demonstrates that cannabis use disorder and withdrawal syndrome are recognized psychiatric conditions with measurable symptomatology that can guide clinical management. Current data supports a combination approach using cognitive-behavioral therapy as first-line treatment, with pharmacologic options including gabapentin, buspirone, and selective serotonin reuptake inhibitors showing promise for managing withdrawal symptoms such as irritability, sleep disturbance, and anxiety. Cannabis withdrawal, though generally less severe than alcohol or opioid withdrawal, can significantly impair functioning and increase relapse risk, particularly in heavy users and those with comorbid psychiatric conditions. Age-specific considerations are important, as adolescents show different neurobiological vulnerability to cannabis dependence compared to adults, while older adults may experience more complex medication interactions and psychiatric comorbidities. Treatment outcomes improve substantially when withdrawal management is combined with psychosocial support and management of underlying depression or anxiety that frequently co-occurs with cannabis use disorder. Clinicians should assess all patients for cannabis use disorder using standardized screening tools and offer evidence-based withdrawal management, as timely intervention during the acute withdrawal period significantly increases long-term abstinence rates.
“What we’re seeing in the peer-reviewed literature on cannabis withdrawal is that it’s real and measurable in a subset of heavy users, though typically milder than alcohol or opioid withdrawal. The clinical challenge now is matching patients to the right interventions, whether that’s behavioral therapy, symptom management, or in some cases judicious use of medications like CBT or low-dose sleep aids, rather than assuming one approach fits everyone.”
💊 As cannabis legalization expands and potency increases, clinicians may encounter more patients seeking treatment for cannabis use disorder and withdrawal symptoms, particularly in geriatric and adolescent populations where neurobiological vulnerabilities differ. Current evidence supports cognitive-behavioral therapy and motivational interviewing as first-line psychosocial interventions, though pharmacological options remain limited and inconsistently effective across patient subgroups. The complexity lies in distinguishing cannabis withdrawal from underlying psychiatric conditions, comorbid substance use, and age-related factors that influence treatment response and tolerability of adjunctive medications. Clinicians should maintain a developmental and developmental lens when assessing dependence severity, as adolescents may present with different withdrawal profiles and treatment needs than older adults with comorbid medical conditions. In practice, a structured assessment of withdrawal severity combined with matched psychosocial support tailored to the patient’s age and psychiatric history offers the most evidence-based approach while
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
